

CytomX Therapeutics, Inc. Logo

## CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

October 31, 2024 at 8:00 AM EDT

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at <https://ir.cytomx.com/events-and-presentations>. An archived replay of the webcast will be available on the Company's website.

Audio Conference Call:

U.S. Dial-in Number: (800) 715-9871

International Dial-in Number: (646) 307-1963

Conference ID: 5171678

### About CytomX Therapeutics, Inc.

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engagers, and immune modulators such as cytokines. CytomX's clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit [www.cytomx.com](http://www.cytomx.com) and follow us on [LinkedIn](#) and [X \(formerly Twitter\)](#).

### Company Contact:

Chris Ogden  
Chief Financial Officer  
[cogden@cytomx.com](mailto:cogden@cytomx.com)

### Investor Contact:

Precision AQ (formerly Stern Investor Relations)  
Stephanie Ascher  
[stephanie.ascher@precisionaq.com](mailto:stephanie.ascher@precisionaq.com)

### Media Contact:

Redhouse Communications  
Teri Dahlman  
[teri@redhousecomms.com](mailto:teri@redhousecomms.com)



Source: CytomX Therapeutics Inc.